224 related articles for article (PubMed ID: 29325228)
1. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
Keller S; Zwingenberger G; Ebert K; Hasenauer J; Wasmuth J; Maier D; Haffner I; Schierle K; Weirich G; Luber B
Mol Oncol; 2018 Apr; 12(4):441-462. PubMed ID: 29325228
[TBL] [Abstract][Full Text] [Related]
2. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
Ebert K; Zwingenberger G; Barbaria E; Keller S; Heck C; Arnold R; Hollerieth V; Mattes J; Geffers R; Raimúndez E; Hasenauer J; Luber B
BMC Cancer; 2020 Oct; 20(1):1039. PubMed ID: 33115415
[TBL] [Abstract][Full Text] [Related]
3. Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
Ebert K; Haffner I; Zwingenberger G; Keller S; Raimúndez E; Geffers R; Wirtz R; Barbaria E; Hollerieth V; Arnold R; Walch A; Hasenauer J; Maier D; Lordick F; Luber B
BMC Cancer; 2022 Mar; 22(1):254. PubMed ID: 35264144
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
[TBL] [Abstract][Full Text] [Related]
5. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
[TBL] [Abstract][Full Text] [Related]
6. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Afatinib and Lapatinib Against
Nakata S; Fujita M; Nakanishi H
Anticancer Res; 2019 Nov; 39(11):5927-5932. PubMed ID: 31704817
[TBL] [Abstract][Full Text] [Related]
8. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
9. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
10. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
11.
Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
[TBL] [Abstract][Full Text] [Related]
12. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
14. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
[TBL] [Abstract][Full Text] [Related]
15. Cancer-adipose tissue interaction and fluid flow synergistically modulate cell kinetics, HER2 expression, and trastuzumab efficacy in gastric cancer.
Akutagawa T; Aoki S; Yamamoto-Rikitake M; Iwakiri R; Fujimoto K; Toda S
Gastric Cancer; 2018 Nov; 21(6):946-955. PubMed ID: 29696406
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
Yoshioka T; Shien K; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Asano H; Soh J; Tsukuda K; Nagasaka T; Fujiwara T; Toyooka S
Cancer Sci; 2018 Apr; 109(4):1166-1176. PubMed ID: 29465762
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
18. Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer.
Park J; Kang SK; Kwon WS; Jeong I; Kim TS; Yu SY; Cho SW; Chung HC; Rha SY
Sci Rep; 2023 Dec; 13(1):22648. PubMed ID: 38114573
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
20. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]